相关实验视频
Updated: Jul 6, 2025
04:44
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
275
改变神经和精神疾病治疗发展的轨迹
Dimitri Krainc1, William J Martin2, Bradford Casey3
1Davee Department of Neurology, Simpson Querrey Center for Neurogenetics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Science translational medicine
|January 8, 2024
概括
新兴技术可以通过允许更好的患者分层和监测来改善神经精神疾病的临床试验. 标准化数据和优先考虑参与者多样性对于成功和解决健康差异至关重要.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 生物标志物发现发现
背景情况:
- 针对中枢神经系统疾病的临床试验因患者异质性而面临挑战,导致高失败率.
- 在试验种群中未被识别的疾病使得疾病机制和进展的阐明变得复杂.
研究的目的:
- 讨论新兴技术和数据集在改善神经精神疾病临床试验方面的潜力.
- 强调需要加强患者分层,监测和解决健康差异的需要.
主要方法:
- 对神经精神疾病相关的新兴技术和数据集的审查.
- 讨论数据标准化和共享的重要性.
- 强调优先考虑研究参与者的多样性.
主要成果:
- 新兴技术为更好地了解疾病机制提供了潜力.
- 生物标志物识别可以改善患者分层和监测.
- 标准化数据收集和共享对于试验效率至关重要.
结论:
- 整合先进技术和多样化的数据集可以优化中枢神经系统疾病的临床试验.
- 优先考虑参与者的多样性是减少研究中的医疗保健差异的关键.
相关概念视频
01:28Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:26Drug Administration and Therapy Phases: Overview
471
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
471
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
657
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
657